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ABSTRACT 
 
Context:  Recreational use of Synthetic Cannabinoid Receptors Agonists (SCRAs) has 
become increasingly common in many countries and may cause severe toxic effects.   
 
Objective:  To describe the clinical features of toxicity in 7 men after analytically 
confirmed exposure to use of MDMB-CHMICA, a recently described indole-based SCRA. 
 
Materials and methods: Clinical information and biological samples (blood, urine) were 
collected from patients with severe toxicity after suspected use of novel psychoactive 
substances. Samples were analysed by High Performance Liquid Chromatography (HPLC) 
data-independent liquid chromatography–tandem mass spectrometry (LC-
MS/MS)analysiscoupled to a TripleTOF® 5600+ mass spectrometer and data 
independent liquid chromatography–mass spectrometry (LC-MS/MS) analysis 
performed using MS/MSALL with SWATH Acquisition. 
 
Case reports: All 7 cases were men who presented to hospitals in England between July 
and October 2015;  6;   reported6 reported smoking ‘legal high’ products. In all cases 
MDMB-CHMICA was identified in blood samples taken on admission to hospital. Other 
substances were identified in 4 cases (methadone 1, methiopropamine 1, other SCRAs 
2).  Clinical features in all 7 cases and in the 3 exposed to MDMB-CHIMICA alone  
included acidosis (7/7 and 3/3) which was respiratory (3/7 and 3/3), metabolic (3/7 and 
0/3) or mixed (1/7, 0/3), reduced level of consciousness (6/7 and 3/3), mydriasis (5/7 
and 3/3), tachycardia (5/7 and 2/3), bradycardia (2/2 7 and 1/3), tonic-clonic 
convulsions (2/7 and 1/3) and agitation (3/7 and 1/3). Recovery occurred within 24 
hours in all cases except one male also exposed to methiopropamine. 
Conclusions:  Analytically confirmed exposure to MDMB-CHMICA was associated with 
acidosis (often of respiratory origin), reduced level of consciousness, mydriasis, heart 
rate disturbances and convulsions.   
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INTRODUCTION 
 
Presentations to emergency departments involving novel psychoactive substances (NPS) 
have become common in many countries and a large number of different substances 
compounds have been implicated.  The Identification Of Novel psychoActive Substances 
(IONA) study began collecting biological samples and clinical data from patients 
presenting to participating hospitals in the United Kingdom with suspected severe 
toxicity after NPS use in March 2015. The study aims to identify the substances involved 
in these episodes of toxicity by analysis of samples taken from affected patients and to 
link these with the clinical effects reported. 
 
Synthetic cannabinoid receptor agonists (SCRA) are one group of NPS that have been 
increasingly encountered internationally as causes of severe toxic effects in users. As 
well as being agonists at cannabinoid receptors (CB1 and CB2), they may have other 
biological actions and these may explain differences in severity and features  of toxicity 
reported in SCRA users compared to those using cannabis. The increasing international 
use of SCRAs may reflect their uncontrolled legal status in many countries and the fact 
that they are not detected by routine urine drug screens [1. Trecki et al, 2015; 2. Tait et 
al 2016; 3. Waugh et al 2016]. 1-3 Here  
 
In this paper we report clinical details of 7 males presenting to 4 English hospitals with 
clinical toxicity associated with analytically confirmed  exposure to the indole-based 
SCRA termed MDMB-CHMICA (IUPAC name 2-[[1-(cyclohexylmethyl)indole-3-
carbonyl]amino]-3,3-dimethylbutanoate, sometimes also called MMB-CHMINACA), a 
substance first detected in Europe in 2014.4 Its chemical structure is shown in the figure. 
Six of these gave a history of using branded ‘legal high’ smoking products.  These data 
are being reported to document the clinical features observed in patients with severe 
toxicity after confirmed exposure to MDMB-CHMICA. 
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METHODS 
 
The IONA study is based in the United Kingdom and open to participation by hospitals 
that assess patients presenting with acute recreational drug toxicity. By February 2016 
there were 11 hospitals recruiting or ready to recruit participants, with a further 16 
hospitals expressing interest or in the set up phase. 
 
The study is recruiting suspected NPS users who are at least 16 years of age presenting 
to participating hospitals with at least one defined feature of severe toxicity. These 
include fever (> 38.5 oC), clinically important hypothermia, reduced level of 
consciousness (Glasgow Coma Scale < 8), critical care or high dependency unit 
admission, respiratory insufficiency, requirement for intubation and ventilation, seizure, 
hallucinations or psychosis, extreme agitation, severe or prolonged (> 24 h) behavioural 
disturbance, arrhythmia, chest pain or ECG evidence of cardiac ischemia or myocardial 
infarction, acidosis (arterial or venous pH < 7.35 or bicarbonate < 20 mmol/l), severe 
electrolyte or fluid disturbances, hypoglycaemia (<1.7 mmol/l), methaemoglobinaemia 
(>50%), tachycardia > 140 /min, systolic hypertension or hypotension (> 180 or <80  
mmHg), acute kidney injury, elevated creatine kinase (> 1000 IU/l), alanine or aspartate 
transaminase (ALT or ALT> 300 IU/L), prothrombin time (PT> 15 s) or International 
Normalised Ratio (INR > 1.3), or a Poisons Severity Score of 3 (severe) or 4 (fatal), or any 
other severe manifestation of toxicity as determined and justified by the investigator.  
 
The IONA study has ethical and research governance approval in England & Wales and 
separately in Scotland because of differences in the law concerning adults with 
incapacity. All potential participants are asked to give fully informed written consent for 
provision of clinical data and samples for toxicological analysis, where they are judged 
by their clinicians to have the mental capacity to do this. Those who do not have 
capacity to make a decision about participation, for example those with severe 
confusion or who are unconscious or intubated can be included on the advice of a 
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personal (usually a family member) or professional (a health professional independent 
of the study) representative. These are termed ‘consultees’ in England and Wales and 
‘appropriate persons with relevant powers’ in Scotland. Those included on the basis of 
such advice are asked to consent if and when they regain capacity. 
 
Following consent (or on the advice of a consultee/person with relevant powers), 
residual blood from samples previously taken for clinical reasons can be used for the 
study and further samples of blood and urine can also be taken at clinically appropriate 
intervals until recovery from toxicity. These samples are provided to the Health 
Protection Research Unit at Newcastle University, together with summary information 
about the patient including basic demographic details, details of the exposure, clinical 
and laboratory features observed and clinical outcome. These data are provided in 
linked anonymized format, identified by a specific code number that can only be linked 
with the participant’s identity by the clinicians at the participating hospital. 
 
Laboratory Analysis  
Samples were analysed by liquid chromatography–tandem mass spectrometry (LC-
MS/MS), consisting of a Sciex TripleTOF® 5600+ high-resolution QqTOF mass 
spectrometer with a DuoSpray ion source operated in positive electrospray (ESI+) mode, 
coupled with an Eksigent Nano LC 420 system, using non-targeted data independent LC-
MS/MS techniques. The particular data independent analysis method employed was 
Sequential Window Acquisition of all THeoretical fragment-ion spectra (SWATH) mass 
spectrometry (MS), which utilises the very fast scanning speeds of quadrupole time-of-
flight (QTOF) mass spectrometers. SWATH MS is a form of data independent analysis 
that repeatedly cycles through consecutive pre-set precursor ion isolation windows, 
detecting all fragment ion spectra from all the precursor ions contained in a specific 
window at a given time, providing highly selective MS/MS mass spectra of all analytes. 
Protonated molecular ions were detected via a time-of-flight (TOF) MS scan covering the 
100 to 700 Da mass range. SWATH MS/MS data were acquired in high sensitivity mode, 
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at a mass resolution of at least 20,000, with a collision energy spread of 30±15V over a 
mass range of 30 to 725 Da, and a 20 Da SWATH isolation window. Mass calibration was 
performed every second sample by injection of a calibration solution through the LC-
MS/MS system. 
 
Chromatographic separation was performed with an ACE C18 capillary LC column – 
100mm x 300µm x 3µm. The column oven and autosampler were maintained at 30 °C 
and 8 °C respectively. Gradient elution was performed with (A) 0.1 % formic acid in 
water and (B) 0.1%formic acid in acetonitrile at a flow rate of 5µL/min. Initial gradient 
conditions were 5 % B, held for 1min; then increased to 95 % B over 20 min, held until 
25 min; and returned to 5 % B at 25.1 min and held until 30.0 min.  
 
Psychoactive substances were extracted from 250μL of plasma or 1mL of urine using 
solid supported liquid/liquid extraction. Samples were diluted with an equal volume of 
de-ionised water and centrifuged at 15,000g for 5 minutes. Samples were then 
transferred onto supported liquid extraction (SLE) columns and gently driven onto the 
column phase with a short pulse of vacuum. After equilibration at ambient pressure for 
5 min, analytes were eluted with 500µL of ethylacetate into polypropylene tubes. A 
further aliquot of 500µLof ethylacetate was applied and allowed to flow for another 5 
minutes before the application of vacuum for 10–20 seconds to elute any remaining 
extraction solvent. The combined sample eluates were evaporated to dryness under a 
stream of nitrogen at 45 °C in a Zymark TurboVap. Samples were reconstituted in 25 μL 
mobile phase A/B 90:10 (v/v), vortexed and centrifugated at 4,000g for 5 min, and 
transferred to amber autosampler vials containing 300-μL glass inserts. A 1µL aliquot 
was used per analysis. 
Psychoactive substances are extracted from 250μL of plasma or 1mL of urine using solid 
supported liquid/liquid extraction. Samples are analysed by High Performance Liquid 
Chromatography (HPLC) coupled to a TripleTOF® 5600+ mass spectrometer. Data 
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independent liquid chromatography–mass spectrometry (LC-MS/MS) analysis is 
LC-MS/MS data were processed using MasterView software version 2.2 with SWATH 
MicroApp version 2.0.  Compounds were identified by software-assisted library 
searching against reference spectra. Library searching and analyte identification were 
performed on MS-MS data with LibraryView version 1.0 and ChemSpider Library version 
2.0 integrated within the MasterView software. The intensity factor determining impact 
of spectral intensity differences between the acquired and the reference spectrum on 
the purity percentage was adjusted to 3. The intensity threshold utilized to remove 
small peaks under a specific intensity was set to 5. Identification criteria were a library 
match with a purity score greater than 65% and the presence of the molecular ion and 
three characteristic MS-MS fragment ions. Positive matches obtained from this search 
are checked by manual review. 
, Library View version 1.1 and ChemSpider Library version 2.0 (AB Sciex). For compound 
identification, extracted ion chromatograms (XICs) of precursor ions are generated with 
the peak finding algorithm integrated in MasterView and MS/MS spectra are submitted 
to Library View and ChemSpider. Positive matches obtained from this search are 
checked by manual review. 
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RESULTS 
 
Case series 
Laboratory analysis of samples from 49 early participants in the IONA study identified 
MDMB-CHMICA was identified in biological samples from seven male patientss 
presenting who had presented with severe toxicity after use of a NPS to participating 
hospitals in Liverpool (1), London (1), Manchester (1) and Newcastle (4) with severe 
toxicity after use of a NPS. All of these patients presented between July and October 
2015. Clinical details are summarized in Table 1the table. For cases 1-3 no other 
substances were identified. Full blood count, urea, electrolytes, creatinine, liver function 
tests and creatine kinase were normal on admission unless otherwise stated. 
 
Case 1 was a 41 year old man with a history of frequent NPS use including uneventful 
SCRA use. He was found collapsed outside with a reduced level of consciousness after 
smoking a product called ‘Sweet Leaf’. On arrival in hospital he was drowsy with a 
Glasgow Coma Scale (GCS) of 11) with and had a bradycardia. Venous blood showed 
hypercapnia and acidosis (Table 1Table) but normal renal and liver function. MDMB-
CHMICA was identified in blood taken at the time of admission; no other controlled or 
recreational substances were detected.   He made an uneventful recovery without 
specific treatment and was discharged 22h after admission. MDMB-CHMICA was 
identified in plasma taken at the time of admission; no other controlled or recreational 
substances were detected.    
 
Case 2, a 16 year old male with a past history of Attention Deficit Hyperactivity Disorder 
for which he was prescribed methylphenidate, was found unconscious at a bus station 
after smoking ‘Sweet Leaf’. On arrival at hospital his GCS was 13 and arterial blood gases 
revealed a mild respiratory acidosis (Table 1). He had a normal full blood count, 
coagulation, urea, electrolytes, liver function and creatine kinase. His conscious level 
gradually improved and he was discharged 18h after admission. MDMB-CHMICA was 
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identified in blood plasma taken at the time of admission but no other controlled or 
recreational substances were identified.  
 
Case 3 was a 33 year old male who was found collapsed on the street with a witnessed 
tonic-clonic seizure. On arrival of the paramedics he had a heart rate of 120 bpm, BP of 
145/59 mmHg and GCS of 3/15.  He was treated with intravenous diazepam 10 mg for 
seizures and transferred to hospital. His GCS improved to 9/15 on route and was 14/15 
on arrival at the hospital. Iin the Emergency Department he was agitated, paranoid and 
violent towards staff, requiring physical restraint. Intravenous access was established 
and was given IV fluids.  Blood tests revealed increases in creatine kinase (CK, 525 IU/L), 
alanine transaminase (ALT, 81 IU/L) and bilirubin (41 IU/L). Venous blood gases, taken 1 
hour after the diazepam administration, showed a predominantly respiratory acidosis 
with a high lactate (Table 1). The electrocardiogram was normal. The patient improved 
over the next few hours and he denied any substance use. He took his own discharge 
against medical advice 5 ½ h after arriving at the hospital. Analysis of a blood sample 
taken 1 hour after admission revealed MDMB-CHMICA, but no other recreational 
substances. 
 
Case 4  was a 16 year old male who collapsed in his home after smoking a product called 
‘Pandora Reborn’. He was found by his parents with generalized shaking consistent with 
a tonic-clonic seizure, which terminated without specific treatment. On arrival in 
hospital he was drowsy but the Glasgow Coma Scale (GCS) was 15/15. Bradycardia, 
mydriasis, hypercapnia and a mixed acidosis were recorded (Table 1). Otherwise routine 
blood tests including renal and liver function were normal. An electrocardiogram (ECG) 
G showed incomplete right bundle branch block. He made an uneventful recovery 
without specific treatment and was discharged 24h after admission. He made an 
uneventful recovery and was discharged the following day. MDMB-CHMICA was 
identified in blood plasma taken at the time of admission. Methadone was also 
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identified, but no other controlled or recreational drugs were detected. MDMB-CHMICA 
was also identified in a urine sample provided 10h after admission. He made an 
 
Case 5 was a 23 year old male with a history of daily recreational drug use including 
various ‘legal highs’, cannabis and diazepam who was also prescribed quetiapine. He 
presented with a 3 day history of abnormal behavior with increasing auditory and visual 
hallucinations, unsteadiness, falls, sweating, agitation, aggression, insomnia and self-
injuring (including head banging).  On arrival in hospital he was aggressive and 
uncooperative with pyrexia, tachycardia, dilated pupils and a mild metabolic acidosis 
(Table 1).   Urine screen was positive for benzodiazepines but no other recreational 
substances. Lorazepam 3mg was administered intravenously before he could be 
formally assessed. He became increasingly agitated in spite of this with a marked 
tachycardia (150 beats/min) and required physical restraint. He was intubated and 
ventilated. Venous blood samples demonstrated increases in white cell count (28.03 
x109/L), Urea urea (15.1 mmol/L), lactate (3.0 mmol/L) and creatine kinase (13,764 
IU/L). CA omputed tomography (CT) brain scanof the brain,  and an ECG, Chest X-ray and 
Lumbar lumbar puncture were all normal.  Urine screen was positive for 
benzodiazepines but no other recreational substances. PInitially phenylephrine and 
subsequently noradrenaline were needed to maintain his blood pressure but he was 
gradually weaned off inotropic support and ventilation and was extubated the day after 
admission. He remained agitated and aggressive for several days requiring large doses 
of benzodiazepines and haloperidol but was subsequently discharged 9 days after 
admission with no sequelae. On recovery he gave a history of smoking a product called 
‘Vertex’. MDMB-CHMICA and methiopropamine were detected in blood  plasma 
samples taken on admission, as well as the lorazepam that had been administered in 
hospital, but no other substances were identified. 
 
Case 6 was a 42 year old man a past history of schizophrenia found naked and confused 
at a bus stop after smoking ‘Black Mamba’. Initial assessment by paramedics reported a 
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GCS of 13 with unequal pupils, cyanosis, tachycardia and tachypnea. Venous blood gases 
on admission revealed a metabolic acidosis with hyperlactataemia which rapidly 
normalized within 6 hours of admission. Other blood tests showed raised total white cell 
count of 15.6 x109/l (Neutrophils 13.3 x109/l) and potassium of 5.6 mmol/l but no other 
changes from previous samples. He was treated with intravenous fluids and sedation, 
his recovery was uncomplicated and he was discharged 18 hours after admission. 
MDMB-CHMICA and 5F-ADFB-PINACA - (IUPAC name N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide  - ) were identified in 
blood plasma taken on admission and also in a urine sample taken 15h after admission. 
 
Case 7, a previously healthy 57 year old male, collapsed after drinking 4-6 cans of 
“strong lager” and smoking a preparation called “Old Spice”. On arrival in the 
Emergency Department he was significantly hypothermic (Core temperature 31 oC), with 
a lactate of 2.9 mmol/L. hHis GCS was 14/15, pulse 89 /min and systolic blood pressure 
50 mmHg. This quickly improved to normal with intravenous fluids. Venous blood gases 
showed pH 7.28, pCO2 6.30 and base excess – 4.1 mmol/L. mild acidosis, a base deficit 
and an elevated lactateRoutine biochemistry analysis did not demonstrate any 
abnormalities . Aand a CT brain scan of his head was normal. Blood ethanol 
concentration was not measured. He rapidly recovered and discharged himself against 
medical advice eight hours after admission.  MDMB-CHMICA was identified in blood 
plasma samples and in a urine sample taken 5 hours after admission, together with 5F-
ADPADB-PINACA and AB-PINACA -(IUPAC name N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
1-pentyl-1H-indazole-3-carboxamide .). 
 
 
DISCUSSION 
 
MDMB-CHMICA (derived from methyldimethylbutanoate cyclohexylmethylindol-
carboxamide) was first notified to the European Monitoring Centre for Drugs and Drug 
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Addiction (EMCDDA) following a seizure of product in Hungary in August 2014.[4. Franz 
Here In this paper we have described the clinical features of seven male patients 
presenting to hospital with toxicity associated with analytically confirmed exposure to 
MDMB-CHMICA.  
 
Three of these cases had isolated MDMB-CHMICA exposure. In this case series, 
documented features may be contributed to by other substances also identified in 4 
cases, but there were 3 cases who had isolated MDMB exposure. Common features 
described were Common clinical features described in all of these were a reduced level 
of consciousness, respiratory acidosis which was respiratory in origin in all 3 cases with 
isolated exposure, mydriasis and heart rate disturbances.  Confusion  Seizures and or 
behavioral disturbances were also documented and convulsions were recorded in 2 one 
case eachs, one exposed to MDMB-CHMICA alone.  
 
In the other 4 cases, documented exposure to other substances may have contributed 
to the clinical features observed. The 
 
MDMB-CHMICA (derived from methyldimethylbutanoate cyclohexylmethylindol-
carboxamide) was first notified to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) following a seizure of product in Hungary in August 2014.4 There 
was a further substantial seizure of 40 kg MDMB-CHMICA in Luxembourg in December 
2014. 5 An EMCDDA alert that was subsequently published by Police Scotland stated that 
as of 20th January 2016, 13 reports had been received describing fatalities, including 8 
cases where it was considered that the drug caused or contributed to death, as well as 
23 non-fatal intoxications associated with MDMB-CHMICA.6 A published report from 
Norway described the sudden cardiac death of a 22 year old male after smoking a 
brown powder, where samples of serum and powder were found to contain MDMB-
CHMICA. 7 Loss of consciousness and asystole were reported in a 25 year old Polish man 
after smoking a legal high product. Although initially resuscitated, he died a few days 
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later from multi-organ failure; MDMB-CHMICA was detected in antemortem blood 
samples. 8 An alert from Wales described a young male who developed dizziness, 
nausea, breathlessness, chest pains, irregular heart beat and convulsions after inhaling 
from a rolled cigarette found to contain MDMB-CHMICA.9  
Most of the clinical features recorded here after exposure to MDMB-CHMICA, including 
seizures and acidosis, have been previously reported with other SCRAs [2. Tait et al 
2016]. 2 Mydriasis, tachycardia, nausea and vomiting, paranoia, hallucinations, 
confusion, agitation, breathlessness, drowsiness, unconsciousness or coma, severe 
motor impairment and loss of sphincter control have been reported following MDMB-
CHMICA exposure. 6 [6. Police Scotland 2016].   Respiratory depression evidenced by 
hypercapnia, however, has not been well documented after SCRA use but was observed 
in all 3 of our patients with isolated MDMB-CHMICA exposure. This is may be a plausible 
effect of SCRAs; in rats, cisternal injection of the SCRA WIN55212-2 produced reductions 
in minute volume and respiratory rate that were prevented by CB1 receptor 
antagonism. 10 [10. Pfitzer et al, 2004]It should be acknowledged, however, that these 
effects may depend on the mode of administration and the dose used and that there 
are  differences in chemical structure and effects between WIN55212-2 and MDMB-
CHMICA. 
 
Like other so-called ‘third generation’ SCRAs, MDMB-CHMICA is not currently controlled 
in the UK, 11 [11. ACMD 2014] although it is a scheduled/controlled substance in some 
countries including Germany, Austria, China, Switzerland, as well as the State of 
Louisiana. The UK situation reflects the increasing difficulty in defining controls for 
SCRAs based on chemical structures because of the diversity involved. The Psychoactive 
Substances Act 2016 2016 soon coming into force in the UK in April 2016 will make it an 
offence to produce, supply or possess with intent to supply any non-exempted 
substance capable of producing a psychoactive effect, including SCRAs.12 [12. National 
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Archives 2016] The impact of this legislation on the patterns of toxicity observed with 
substances requires careful monitoring.  
 
Clinical toxicologists and Poisons Centers should be aware of the potential toxicity of 
SCRAs such as MDMB-CHMICA. TIn conclusion, these analytically confirmed cases 
suggest that MDMB-CHMICA can cause a reduction in level of consciousness associated 
with hypercapnia, confusion, tachycardia or bradycardiaheart rate disturbances, 
mydriasis and in some cases convulsions and behavioural disturbances. Clinical 
toxicologists and Poisons Centers should be aware of the potential effects of SCRAs 
including MDMB-CHMICA to inform recommendations on appropriate patient 
monitoring and treatment. 
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Table 1. Clinical features of 7 males exposed to MDMB-CHMICA, with observations as recorded on admission to hospital. 
No Age Reported exposures Route Analytical 
confirmation
Features Temp GCS HR SBP DBP RR Mydriasis pH pCO2 pO2 BE Lactate LOS
(y) oC /min mmHg mmHg /min - kPa kPa mMol/L mMol/L h
Lower limit of normal* 36.1 15 50 100 60 12 - 7.35 4.7 12 -3
Upper limit of normal* 37.2 15 90 140 90 20 - 7.45 6 15 3 1.9
1 41 Sweet Leaf' ,      Black 
mamba 
Smoked MDMB-CHMICA Reduced level of 
consciousness, bradycardia
36.4 11 44 96 60 12 Yes 7.29 9.25 VG 4.2 0.6 24
2 16 Sweet Leaf' 
.Prescribed 
methylphenidate
Smoked MDMB-CHMICA Reduced level of 
consciousness, tachycardia
36.7 13 120 116 57 19 Yes 7.31 7.47 11.57 0.2 0.7 18
3 33 Not known NK MDMB-CHMICA Reduced level of 
consciousness, tonic-clonic 
convulsion, tachycardia,  
acidosis, behavioural 
disturbance
36.7 14 120 145 59 14 Yes 7.22 10.4 VG 1.2 4.6 5.5
4 16 Pandora Reborn' Smoked MDMB-CHMICA, 
methadone
Collapse. tonic-clonic 
convulsion, bradycardia, 
mydriasis
35.1 10 49 113 53 16 Yes 7.33 7.5 11.3 -5.0 1.2 22
5 23 Vertex'.      Frequent 
use of cannabis and 
diazepam. Prescribed 
quetiapine
NK MDMB-CHMICA 
methiopropamine 
Lorazepam**
Aural and visual 
hallucinations, ataxia with 
falls, sweating, agitation, 
aggression, insomnia, self-
injuring  
38.1 15 100 110 64 n/a Yes 7.31 4.32 30.5 -9.2 1.13 189
6 42 Black mamba' Smoked MDMB-CHMICA, 5F-
ADB-PINACA
Reduced level of 
consciousness, confusion, 
tachycardia, tachypnoea, 
acidosis
35.5 13 123 114 91 60 No 7.2 3.97 19.35 -15.0 >20 11.5
7 57 Old Spice', Alcohol Smoked MDMB-CHMICA, 5F-
ADB-PINACA,  AB-
PINACA
Collapse, hypothermia,  
hypotension, acidosis
34.8 14 96 50 - 15 No 7.28 6.3 VG -4.1 2.9 8.5
 
*Upper and lower limits of normal used may vary between hospitals. **Administered in hospital.  
GCS = Glasgow Coma Scale; HR = heart rate; SBP = Systolic blood pressure; DBP = diastolic blood pressure; RR = Respiratory Rate; BE = base excess; 
LOS = Length of hospital stay; VG = Venous blood gases; NK = not known;
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Figure 1: Chemical structure of MDMB-CHMICA 
 
